[{"id":"6bcc3ec1-9063-4f23-ae4a-205ce27b321c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02725606","created_at":"2021-01-18T13:20:29.208Z","updated_at":"2024-07-02T16:37:18.703Z","phase":"Phase 1","brief_title":"Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer","source_id_and_acronym":"NCT02725606","lead_sponsor":"Jiangsu T-Mab Biopharma Co.,Ltd","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GW003 (balugrastim biosimilar)"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 09/01/2017","primary_completion_date":" 09/01/2017","study_txt":" Completion: 09/01/2017","study_completion_date":" 09/01/2017","last_update_posted":"2017-08-18"}]